GlassScriptPhysician profile
Jill C Stein
NPI 1689262230
$3,751.40
in general payments reported to CMS, 2019-2025
29 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,231 · 2022: $395 · 2023: $149 · 2024: $487 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $820.66 | 2021-2025 | Evenity, Krystexxa, Prolia |
| Pfizer INC. | $444.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $381.32 | 2021-2024 | Airsupra |
| Janssen Biotech, INC. | $303.26 | 2021-2022 | |
| Abbvie INC. | $218.81 | 2021-2025 | |
| Glaxosmithkline, LLC. | $198.00 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Janssen Scientific Affairs, LLC | $184.38 | 2021-2022 | |
| Ucb, INC. | $152.49 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $142.85 | 2021-2024 | |
| Horizon Therapeutics Plc | $136.33 | 2021 | |
| Aurinia Pharma U.S., INC. | $71.92 | 2021-2022 | |
| Novo Nordisk INC | $63.01 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Sobi, INC | $58.12 | 2021-2022 | |
| Baxter Healthcare | $56.65 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Lundbeck LLC | $54.30 | 2023-2024 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49.56 | 2021-2025 | Mounjaro, Zepbound |
| Radius Health, INC. | $46.26 | 2021 | |
| Phathom Pharmaceuticals, INC. | $45.01 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.57 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $40.43 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $38.90 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Astellas Pharma US INC | $34.15 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $31.39 | 2023-2025 | Eliquis |
| Currax Pharmaceuticals LLC | $31.10 | 2024-2025 | Contrave |
| Abbott Laboratories | $27.50 | 2025 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $27.46 | 2024-2025 | Nuzyra, Xhance |
| Cipher Pharmaceuticals US LLC | $19.82 | 2025 | Natroba, Spinosad |
| Depuy Synthes Sales INC. | $18.54 | 2021 | |
| Organon LLC | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.